ArticleMolecular and cellular biochemistry2015
NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma.
Article in Molecular and cellular biochemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- In vitro and in silico analysis of the anti-proliferative effects of Spirulina platensis on A549 lung cancer cells.Scientific reports · 2025Article
- Multi-omics analysis of ILF2 reveals its prognostic value and functional roles across pan-cancer.Discover oncology · 2025Article
- USP5-mediated stabilization of ILF2 via deubiquitination drives the tumor growth of colorectal cancer.American journal of cancer research · 2025Article
- Single-cell RNA sequencing elucidated the landscape of breast cancer brain metastases and identified ILF2 as a potential therapeutic target.Cell proliferation · 2024Article
- ILF2: a multifaceted regulator in malignant tumors and its prospects as a biomarker and therapeutic target.Frontiers in oncology · 2024Review
- Metabolomic Characterization Reveals ILF2 and ILF3 Affected Metabolic Adaptions in Esophageal Squamous Cell Carcinoma.Frontiers in molecular biosciences · 2021Article
- LncRNA NR038975, A Serum-Based Biomarker, Promotes Gastric Tumorigenesis by Interacting With NF90/NF45 Complex.Frontiers in oncology · 2021Article
- Cereblon Promotes the Ubiquitination and Proteasomal Degradation of Interleukin Enhancer-Binding Factor 2.The protein journal · 2020Article
- Identification of hub genes and pathways in cholangiocarcinoma by coexpression analysis.Cancer biomarkers : section A of Disease markers · 2020Article
- PRMT6 Promotes Lung Tumor Progression via the Alternate Activation of Tumor-Associated Macrophages.Molecular cancer research : MCR · 2020Article
- Article
- ILF2 cooperates with E2F1 to maintain mitochondrial homeostasis and promote small cell lung cancer progression.Cancer biology & medicine · 2019Article
- ILF2 promotes anchorage independence through direct regulation of PTEN.Oncology letters · 2019Article
- ILF3 promotes gastric cancer proliferation and may be used as a prognostic marker.Molecular medicine reports · 2019Article
- Inducible expression of immediate early genes is regulated through dynamic chromatin association by NF45/ILF2 and NF90/NF110/ILF3.PloS one · 2019Article
- Identification of a novel splice variant of the human musashi-1 gene.Oncology letters · 2018Article
- Interleukin enhancer binding factor 2 is a prognostic biomarker for breast cancer that also predicts neoadjuvant chemotherapy responses.American journal of translational research · 2018Article
- MicroRNA-7 functions as a tumor-suppressor gene by regulating ILF2 in pancreatic carcinoma.International journal of molecular medicine · 2017Article
- Expression and Clinical Significance of ILF2 in Gastric Cancer.Disease markers · 2017Article
- Expression and Critical Role of Interleukin Enhancer Binding Factor 2 in Hepatocellular Carcinoma.International journal of molecular sciences · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NF45, also referred to as nuclear factor of activated T cells, has been reported to promote the progression of multiple cancer types. However, the expression and physiological significance of NF45 in pancreatic ductal adenocarcinoma (PDAC) remain largely elusive. In this study, we investigated the clinical relevance and potential role of NF45 expression in PDAC development. Western blot analysis revealed that NF45 was remarkably upregulated in PDAC tissues, compared with the adjacent non-tumorous ones. In addition, the expression of NF45 in 122 patients with PDAC was evaluated using immunohistochemistry. In this way, we found that NF45 was abundantly expressed in PDAC tissues, and the expression of NF45 was correlated with tumor size (p = 0.007), histological differentiation (p = 0.033), and TNM stage (p = 0.001). Importantly, patients with low levels of NF45 expression exhibited better postoperative prognosis as compared with those with high NF45 expression. Furthermore, using PDAC cell cultures, we found that interference of NF45 expression using siRNA oligos suppressed PDAC cell proliferation and retarded cell cycle progression. Moreover, depletion of NF45 impaired the levels of cellular cyclin E and proliferating cell nuclear antigen (PCNA). Conversely, overexpression of NF45 facilitated the cell growth and accelerated cell cycle progression. Our results establish NF45 as an important indicator of PDAC prognosis with potential utility as a therapeutic target in this lethal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.